John Leone

Directeur/Membre du Conseil chez

Oscient Pharmaceuticals Corp.

79 ans

78 relations

Health Technology

Finance

Consumer Services

Profil

John R.
Leone is currently the Director at Oscient Pharmaceuticals Corp.
and the Operating Partner at Madryn Asset Management LP.
He previously held positions such as President & Chief Executive Officer at Cambrex Corp., Director at InKine Pharmaceutical Co., Inc., Director at Forticell Bioscience, Inc., Independent Director at Windtree Therapeutics, Inc., Independent Director at Shire ViroPharma, Inc., Director of Marketing at Pfizer Pharmaceuticals, Inc., Lead Independent Director at Pernix Therapeutics Holdings, Inc., Vice President & General Manager at Wyeth LLC, Senior Vice President at American Home Products LLC, Senior VP & COO-US Commercial Operations at Aventis Pharmaceuticals, Inc., Partner at Paul Capital Partners LP, Partner at Visium Asset Management LP, Vice President & General Manager at Rhone-Poulenc Rorer Pharmaceuticals, Inc., Principal at Hoechst Marion Roussel, Inc., and Principal at Renata Ltd. He received his undergraduate degree from the US Military Academy and his MBA from The University of Colorado.

Postes actifs de John Leone

Sociétés	Poste	Début
Oscient Pharmaceuticals Corp. Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Markets and sells products to community-based primary care physicians	Directeur/Membre du Conseil	05/12/2007
Madryn Asset Management LP Madryn Asset Management LP Investment ManagersFinance Madryn Asset Management seeks investment opportunities in companies located in the United States. The firm targets companies operating in the fields of biopharma, medtech, diagnostics, life sciences and healthcare information technology. It provides financing for early and later stage capital requirements.	Private Equity Investor	01/02/2017

Tous les postes actifs de John Leone

Anciens postes connus de John Leone

Sociétés	Poste	Fin
WINDTREE THERAPEUTICS, INC.	Président	-
PERNIX THERAPEUTICS HOLDINGS INC	Directeur/Membre du Conseil	01/01/2019
Visium Asset Management LP Visium Asset Management LP Investment ManagersFinance Visium Asset Management seeks to achieve consistent, positive absolute returns by investing in a variety of industry sectors and in a wide range of financial instruments. Such instruments include, but are not limited to, long or short positions in US or non-US publicly traded or privately issued or negotiated common stocks, preferred stocks, stock warrants and rights, corporate or sovereign debt, bonds, notes or other debentures or debt participations, commodities, partnership interests, interests in investment companies, convertible securities, swaps, options (purchased or written), swaptions, futures contracts and other derivative instruments.	Private Equity Investor	01/01/2017
Shire ViroPharma, Inc. Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs	Directeur/Membre du Conseil	01/03/2014
Forticell Bioscience, Inc. Forticell Bioscience, Inc. BiotechnologyHealth Technology Advances regenerative medicine through development of cellular technology & advanced biomaterial products	Directeur/Membre du Conseil	16/09/2008

Voir l'expérience en détail de John Leone

Formation de John Leone

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de John Leone

Relations

Relations au 1er degré

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées	21
Wyeth Corp. Wyeth Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes pharmaceuticals, vaccines & biotechnology products	Health Technology
Cambrex Corp. Cambrex Corp. Pharmaceuticals: GenericHealth Technology Develops and manufactures drug substances	Health Technology
Oscient Pharmaceuticals Corp. Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Markets and sells products to community-based primary care physicians	Commercial Services
InKine Pharmaceutical Co., Inc. InKine Pharmaceutical Co., Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical Products	Health Technology
Forticell Bioscience, Inc. Forticell Bioscience, Inc. BiotechnologyHealth Technology Advances regenerative medicine through development of cellular technology & advanced biomaterial products	Health Technology
Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops novel therapeutics to address significant unmet medical needs in acute care markets	Health Technology
Shire ViroPharma, Inc. Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs	Health Technology
The Vaccine Co. The Vaccine Co. BiotechnologyHealth Technology Develops therapeutic vaccines for the treatment of leukemias and other types of cancers	Health Technology
American Home Products LLC American Home Products LLC Forest ProductsNon-Energy Minerals Designs, fabricates, sells, retails and installs window and door shutters	Non-Energy Minerals
Aventis Pharmaceuticals, Inc. Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products	Health Technology
Pediatric Management Group Pediatric Management Group Medical/Nursing ServicesHealth Services Physician practice management services	Health Services
Paul Capital Partners LP Paul Capital Partners LP Investment ManagersFinance Paul Capital Partners' investment platforms include the Paul Capital Fund of Funds, secondary investments and commercial-stage healthcare investments. The Paul Capital Fund of Funds investment team focuses on investments in venture capital and small-cap buyouts. The firm invests in funds that support innovative products and business models. They take takes a lead investment role and actively seek advisory board seats. Their strategy is both growth and value oriented. The Paul Capital Fund of Funds venture capital investment strategy focuses on providing access to top-tier venture capital managers. The firm looks for emerging managers that have the potential to become industry leaders. They employ a multi-industry investment strategy that focuses on information technology, healthcare and clean technology. Most investments are made in early-stage companies, but some investments are made in late-stage and growth equity to provide reduced volatility and more rapid exits. The strategy is biased towards small funds and is balanced by a short list of larger funds or platforms. Paul Capital invests primarily in funds in the Silicon Valley and Boston, with growing exposure to select international investments. They make secondary investments in top tier managers obtained through the secondary market to mitigate the effect of the typical J-Curve associated with private equity fund investing. The Paul Capital Fund of Funds small-cap buyout investment strategy focuses on investments in a small-cap buyout funds in North America. They invest in small-cap buyout funds that are being raised by managers who are focused on buying companies with enterprise values of $300 million or less. To select the best performing managers, Paul Capital's process begins with a large universe of buyout relationships and ends with a focused and diversified small-cap buyout portfolio. The portfolio is complemented by co-investments and by investments in target funds obtained through the secondary market. The Paul Capital Fund of Funds co-investment strategy focuses on co-investments alongside general partners that are well-known to the firm and who require capital to close pending small-cap buyout and growth equity transactions. Investments are made directly in the securities of the portfolio company. The Fund of Funds team invests directly in portfolio companies across a full range of economic and credit cycles. For investors requiring exposure to both the firm's venture capital and small-cap buyout funds, Paul Capital provides customized solutions that allow participation in both activities over a multi-year period with a desired percentage allocation to each. Large investors seeking increased exposure to emerging managers, growth equity funds or buyout funds larger than their small-cap target (but generally less than $2 billion in size) can be accommodated through a separate account relationship. Paul Capital provides secondary transaction solutions for various sellers including pension plans, financial institutions, endowments, family offices, corporations and general partners. They help sellers reallocate their portfolio across asset types and classes, achieve early liquidity from private equity investments and obtain follow-on capital for existing portfolios and other objectives. Paul Capital Healthcare employs a variety of financing options ranging from non-dilutive financings that include royalty and revenue interest financings, to more traditional instruments such as equity and structured debt. Their clients include public and private companies, academic institutions and inventors. Paul Capital Healthcare helps companies monetize their royalty streams by selling all or a portion of these future royalties in exchange for an upfront payment and, depending on the structure, potential future payments. Paul Capital Healthcare invests in healthcare products that are approved and are generating revenue or are near commercialization. Healthcare companies should have an identifiable and established market, have patent and/or regulatory protection and be marketed by a strong organization. Paul Capital Healthcare employs the use of synthetic royalties or revenue interest financings. The firm provides a company with an upfront payment and future payments in exchange for a percentage of future product revenues. These deals are structured in a way that is similar to licensing agreements. They employ tiered revenues, reverse tiers, minimum payments, caps, step-downs and buy-out options. The deals are different from a standard licensing agreement in that Paul Capital Healthcare is not responsible for commercializing the product and is not involved in the company's daily operations. The firm makes an upfront payment to the company and, in some cases, additional payments based on certain milestones, such as regulatory approvals, patent extensions and sales targets. Paul Capital Healthcare then receives a portion of the future revenues generated by the product(s). Paul Capital Healthcare provides structured debt financing for small to mid-sized healthcare companies looking to expand operations. They can structure mezzanine-like debt in combination with revenue interests or royalty financings and the purchase of equities. Paul Capital Healthcare also structures traditional equity investments, usually in combination with revenue interest and royalty financings. The Fund participates in early-stage financing rounds in syndication with venture funds and in PIPE-style offerings. Paul Capital Healthcare focuses on near market or commercial-stage investments.	Finance
US Military Academy US Military Academy Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
The University of Colorado The University of Colorado Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Visium Asset Management LP Visium Asset Management LP Investment ManagersFinance Visium Asset Management seeks to achieve consistent, positive absolute returns by investing in a variety of industry sectors and in a wide range of financial instruments. Such instruments include, but are not limited to, long or short positions in US or non-US publicly traded or privately issued or negotiated common stocks, preferred stocks, stock warrants and rights, corporate or sovereign debt, bonds, notes or other debentures or debt participations, commodities, partnership interests, interests in investment companies, convertible securities, swaps, options (purchased or written), swaptions, futures contracts and other derivative instruments.	Finance
Rhone-Poulenc Rorer Pharmaceuticals, Inc.
Hoechst Marion Roussel, Inc. Hoechst Marion Roussel, Inc. Pharmaceuticals: GenericHealth Technology Develops, manufactures and sells generic pharmaceutical products	Health Technology
Pfizer Pharmaceuticals, Inc. Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products	Health Technology
Pernix Therapeutics Holdings, Inc. Pernix Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products	Health Technology
Renata Ltd. /Bd/
Madryn Asset Management LP Madryn Asset Management LP Investment ManagersFinance Madryn Asset Management seeks investment opportunities in companies located in the United States. The firm targets companies operating in the fields of biopharma, medtech, diagnostics, life sciences and healthcare information technology. It provides financing for early and later stage capital requirements.	Finance